Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response (Q42677733)
Jump to navigation
Jump to search
scientific article published on 14 August 2014
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response |
scientific article published on 14 August 2014 |
Statements
1 reference
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response (English)
1 reference
1 reference
Michael Untch
1 reference
Edith A Perez
1 reference
Peter Vuylsteke
1 reference
Andrew P Holmes
1 reference
Martine Piccart-Gebhart
1 reference
Eileen Holmes
1 reference
Ramona F Swaby
1 reference
Christian Jackisch
1 reference
Istvan Lang
1 reference
Ian Smith
1 reference
Frances Boyle
1 reference
Binghe Xu
1 reference
Carlos H Barrios
1 reference
Hatem A Azim
1 reference
Sung-Bae Kim
1 reference
Sherko Kuemmel
1 reference
Ruey-Kuen Hsieh
1 reference
Vera Gorbunova
1 reference
Alexandru Eniu
1 reference
Lydia Dreosti
1 reference
Natalia Tavartkiladze
1 reference
Richard D Gelber
1 reference
Holger Eidtmann
1 reference
José Baselga
1 reference
14 August 2014
1 reference
1 reference
15
1 reference
10
1 reference
1137-1146
1 reference
Identifiers
1 reference
1 reference